Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum | Zendy

Mohammed Lamorde | Zendy; Xinzhu Wang | Zendy; Megan Neary | Zendy; Elisa Bisdomini | Zendy; Shadia Nakalema | Zendy; Pauline ByakikaKibwika | Zendy; Jackson Mukonzo | Zendy; Waheed Khan | Zendy; Andrew Owen | Zendy; Myra O. McClure | Zendy; Marta Boffito | Zendy

Open Access

Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum

Author(s) -

Mohammed Lamorde,

Xinzhu Wang,

Megan Neary,

Elisa Bisdomini,

Shadia Nakalema,

Pauline ByakikaKibwika,

Jackson Mukonzo,

Waheed Khan,

Andrew Owen,

Myra O. McClure,

Marta Boffito

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy161

Subject(s) - efavirenz , medicine , pharmacokinetics , pharmacodynamics , viral load , confidence interval , pharmacogenetics , cyp2b6 , nevirapine , postpartum period , pharmacology , pregnancy , therapeutic drug monitoring , area under the curve , gastroenterology , obstetrics , antiretroviral therapy , human immunodeficiency virus (hiv) , virology , genotype , biochemistry , chemistry , genetics , cytochrome p450 , metabolism , cyp3a4 , biology , gene

A clinical trial showed that efavirenz 400 mg once daily (EFV400) is as effective as the standard adult dose. World Health Organization recommends EFV400 as an alternative first-line agent, but data are lacking in the third trimester of pregnancy (TT). We investigated the pharmacokinetics, efficacy, and CYP2B6 pharmacogenetics in HIV-infected women (WLWH) on EFV400 during TT and post-partum (PP).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research